Overall, metabolic syndrome was associated with a 39 percent to 103 percent increased risk of endometrial cancer in women 65 and older, according to the study.
A collection of health risk factors known as the "metabolic syndrome" may boost older women's risk of endometrial cancer, even if they're not overweight or obese, a new study suggests.
Metabolic syndrome refers to a group of health conditions occurring together that increase the risk of heart disease, stroke and diabetes. These conditions include high blood pressure, low levels of "good" HDL cholesterol, high levels of triglyceride fats, overweight and obesity, and high fasting blood sugar.
"We found that a diagnosis of metabolic syndrome was associated with higher risk of endometrial cancer, and that metabolic syndrome appeared to increase risk regardless of whether the woman was considered obese," Britton Trabert, an investigator in the division of cancer epidemiology and genetics at the U.S. National Cancer Institute, said in an American Association for Cancer Research news release.
The study's design only allowed the investigators to find an association between metabolic syndrome and endometrial cancer risk. The researchers couldn't prove whether or not metabolic syndrome directly causes this cancer of the uterine lining.
Link to the complete article on MedlinePlus: http://1.usa.gov/1CrEgii
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More